Invention Grant
- Patent Title: Compounds and compositions for modulating EGFR Activity
- Patent Title (中): 用于调节EGFR活性的化合物和组合物
-
Application No.: US14405773Application Date: 2013-06-05
-
Publication No.: US09440957B2Publication Date: 2016-09-13
- Inventor: Gerald Lelais , Robert Epple , Thomas H. Marsilje, III , Pierre-Yves Michellys , Matthew McNeill , Yun Long , Wenshuo Lu , Bei Chen , Badry Bursulaya , Songchun Jiang
- Applicant: Gerald Lelais , Robert Epple , Thomas H. Marsilje, III , Pierre-Yves Michellys , Matthew McNeill , Yun Long , Wenshuo Lu , Bei Chen , Badry Bursulaya , Songchun Jiang
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Agency: Genomics Institute of the Novartis Research Foundation
- Agent Emily T. Wu
- Priority: IN1741/DEL/12 20120606
- International Application: PCT/US2013/044247 WO 20130605
- International Announcement: WO2013/184757 WO 20131212
- Main IPC: A61K31/55
- IPC: A61K31/55 ; C07D401/14 ; C07D403/04 ; C07D403/14 ; C07D405/14 ; C07D409/14 ; C07D411/14 ; C07D413/14 ; C07D417/14 ; A61K31/4184 ; A61K31/454 ; A61K31/4545 ; A61K31/551 ; A61K31/553 ; A61K45/06 ; C07D401/04 ; C07D413/04 ; C07D471/04 ; C07D513/04
Abstract:
The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating EGFR activity, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated EGFR activity.
Public/Granted literature
- US20150197505A1 Compounds and Compositions for Modulating EGFR Activity Public/Granted day:2015-07-16
Information query
